Claire Chu is an Ophthalmology physician. OpenAlex indexes 27 publications with 2,474 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12222 Merit Dr Ste 1420
Dallas, TX 752512283
Telephone
972-803-5665Provider last certified this registry record 22 Sept 2025.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year202513 payments
- Glaukos CorporationProgram year20251 payment
- United Therapeutics CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
64.2%Corticosteroid24.6%Prednisolone Acetate100%Part D≥287 patientsProstaglandin Analog15.9%Latanoprost85%Lumigan10%Travoprost6%Part D<11 patients+ 6 more classes in this area
Anti-infectives
25.1%Fluoroquinolone Antibacterial23.1%Moxifloxacin100%Part D≥277 patientsTetracycline-class Drug1.2%Doxycycline Hyclate100%Part D≥17 patients+ 1 more class in this area
Cardiovascular
8.9%Beta blocker8.9%Timolol Maleate100%Part D≥39 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Non-Canonical TERT Activity Initiates Osteogenesis in Calcific Aortic Valve Disease
Circulation Research
2025 - Rapamycin reduces mineral density and promotes beneficial vascular remodeling in a murine model of severe medial arterial calcification
American Journal of Physiology-Heart and Circulatory Physiology
2025 - Rapamycin Reduces Mineral Density and Promotes Beneficial Vascular Remodeling in a Murine Model of Severe Medial Arterial Calcification
bioRxiv (Cold Spring Harbor Laboratory)
2024 - Abstract 2040: Rapamycin Extends Life Of Matrix Gla Protein Knockout Mice Independent Of Vascular Calcification Content.
Arteriosclerosis Thrombosis and Vascular Biology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”